Navigation Links
Rabbit Anti-Human DCTN4,DYNACTIN 5 (P25) Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.

ProductsRabbit Anti-Human DCTN4,DYNACTIN 5 (P25) Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
Company Proteintech Group, Inc.
Item Rabbit Anti-Human DCTN4,DYNACTIN 5 (P25) Polyclonal Antibody, Unconjugated
Price $245.00
Description dynactin 4, mRNA (cDNA clone MGC:3248 IMAGE:3505855), complete cds
Info Proteintech Group, Inc.Proteintech Group, Inc.
2201 W. Campbell Park Drive
Chicago, IL 60612
Customer Service: 1-888-4PTGLAB
Fax Number: 1-312-455-8408
Web Site: http://www.ptglab.com
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. Rabbit Anti-Aph-1aL, S Loop (92-115) Polyclonal Antibody, Unconjugated from Covance Research Products, Inc
2. Rabbit Anti-Human Vitamin K-dependent Protein S (PROS1) Polyclonal Antibody, Unconjugated from Lifespan Biosciences
3. Rabbit Anti-Human Sirtuin (silent mating type information regulation 2, S.cerevisiae, homolog) 7 (SIRT7) Polyclonal Antibody, Unconjugated from Lifespan Biosciences
4. Rabbit Anti-Esa1 Polyclonal Antibody, Unconjugated from Abcam
5. Rabbit Anti-Human Rad51 Polyclonal Antibody, Unconjugated from Abcam
6. Human CALCA EIA (Enzyme immunoassay) Kit, Host: Rabbit ; Extraction-free from BACHEM
7. MaxArray Tissue Array (Animal - Rabbit) from Invitrogen
8. Rabbit Anti-GST Polyclonal Antibody, Unconjugated from Novus Biologicals
9. Rabbit Anti-Shigella Polyclonal Antibody, Unconjugated from GeneTex
10. Vaginal Keratinocyte Progenitors, Rabbit from CHEMICON
11. Dermal Fibroblasts, Rabbit from CHEMICON
Hamster serum...
... Kit with CyScribe GFX Purification Kit, ... purification of Cy3- and Cy5-labeled cDNA.Optimized ... cDNA labeling and purification.Flexible and optimized ... labeling reactions with either Cy3- or ...
Canine Serum...
CASPR (H-66)...
Biology Products:
(Date:3/12/2015)... , March 12, 2015 IriTech, a ... a member of the Texas Instruments Design Network, announced ... has demonstrated its IriShield USB MK2120U device during ... facility for pension distribution. The iris ... to be marketed in India ...
(Date:3/12/2015)... March 12, 2015 WHEN:Tuesday, March 17, 2015 ... http://bit.ly/1G7Os0L . SPEAKERS: , Frost & Sullivan ... http://photos.prnewswire.com/prnh/20150311/181111 Biometric companies must ... in several different markets and industries. This is ... an uptrend. Join Frost & ...
(Date:3/10/2015)... NEW YORK , March 10, 2015  Continuing ... and the Unexpected, Hammacher Schlemmer introduces The Eye ... user,s identity before granting access to secure websites or ... trusted to verify travelers at international borders, the device ... 240 distinctive pattern points of the iris, converting them ...
Breaking Biology News(10 mins):Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 3Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2
... working to create "protocells" primitive synthetic cells consisting ... compartment have accomplished an important step towards their ... Science , the investigators describe a solution to ... potential incompatibility between a chemical requirement of RNA copying ...
... a team of UC San Diego biophysicists has discovered ... to multiply in the presence of antibiotics, a growing ... United States. , Two months ago, the Centers for ... that antibiotic-resistant bacteria last year caused more than two ...
... have developed a series of techniques to create a ... the alcohols and amines used in the drug and ... safer and more economical and environmentally friendly than traditional ... extensive supply of iron the fifth most abundant ...
Cached Biology News:Researchers find a missing component in effort to create primitive, synthetic cells 2Researchers find a missing component in effort to create primitive, synthetic cells 3Quantitative approaches provide new perspective on development of antibiotic resistance 2Quantitative approaches provide new perspective on development of antibiotic resistance 3Iron-based process promises greener, cheaper and safer drug and perfume production 2
(Date:3/30/2015)... 2015 CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... commercial focus on China , announced ... has approved the Company,s application to conduct a Phase ... (OCCC) patients for its proprietary drug candidate ENMD-2076.  ...
(Date:3/30/2015)... GERMANTOWN, Md. , March 30, 2015  /PRNewswire/ ... a leader in synthetic biology, and Merck Serono, ... Germany , today announced an exclusive ... commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. ... to develop innovative therapies that modulate the immune ...
(Date:3/30/2015)... UK, and BELLINGHAM, Washington, USA (PRWEB) March 29, 2015 ... projects in Europe and the United States and plenary ... highlights planned for SPIE Optics + Optoelectronics ... feature over 700 technical presentations in 17 conferences alongside ... society for optics and photonics , the event will ...
(Date:3/30/2015)... , March 30, 2015  Naldemedine, an investigational ... by Shionogi & Co., Ltd., met its primary ... (COMPOSE I) for the treatment of opioid-induced constipation ... receiving opioid therapy. Study results showed that naldemedine ... improved the frequency of spontaneous bowel movement (SBM) ...
Breaking Biology Technology:CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3